Stockscreener 앱 받기
8.86
4.22%
-0.39
시간 외 거래:
8.67
-0.19
-2.14%
전일 마감가:
$9.25
열려 있는:
$9.5
하루 거래량:
238.92K
Relative Volume:
1.61
시가총액:
$61.59M
수익:
$46.74M
순이익/손실:
$-114.33M
주가수익비율:
-6.8682
EPS:
-1.29
순현금흐름:
$-21.04M
1주 성능:
+37.15%
1개월 성능:
+84.97%
6개월 성능:
-43.62%
1년 성능:
-86.82%
1일 변동 폭
$8.70
$9.69
1주일 범위
$6.17
$9.69
52주 변동 폭
$3.60
$67.90
Scilex Holding Company Stock (SCLX) Company Profile
명칭
Scilex Holding Company
전화
(650) 516-4310
주소
960 SAN ANTONIO ROAD, PALO ALTO
SCLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SCLX
Scilex Holding Company
|
8.86 | 35.49M | 46.74M | -114.33M | -21.04M | -1.29 |
|
LLY
Lilly Eli Co
|
771.71 | 711.91B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
163.70 | 377.51B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
189.26 | 339.94B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.25 | 234.28B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
64.31 | 306.28B | 43.59B | 15.04B | 10.74B | 3.3766 |
Scilex Holding Company Stock (SCLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-27 | 개시 | D. Boral Capital | Buy |
| 2024-10-16 | 개시 | Alliance Global Partners | Buy |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-10-16 | 개시 | B. Riley Securities | Buy |
| 2023-10-13 | 개시 | B. Riley Securities | Buy |
| 2023-10-09 | 개시 | H.C. Wainwright | Buy |
모두보기
Scilex Holding Company 주식(SCLX)의 최신 뉴스
What drives Scilex Holding Company Equity Warrant stock priceTurbocharged investment results - Jammu Links News
Is Scilex Holding Company Equity Warrant stock a growth or value playFree Stock Market Knowledge Sharing - Newser
What institutions are buying Scilex Holding Company Equity Warrant stock nowCapital Safe Smart Trades - Newser
Is Scilex Holding Company a good long term investmentFree Investment Community - Jammu Links News
Why Scilex Holding Company Equity Warrant stock attracts strong analyst attentionFree Daily Stock Market Updates - beatles.ru
How Scilex Holding Company stock performs during market volatilitySafety First Trading Signals - Newser
What makes Scilex Holding Company stock price move sharplyWeekly Big Movers - Newser
Why Scilex Holding Company stock attracts strong analyst attentionSmall Risk Large Return Trades - Newser
What makes Scilex Holding Company Equity Warrant stock price move sharplyTop Momentum Stock Pick - Newser
How Scilex Holding Company Equity Warrant stock performs during market volatilityFree Access to Investment Community - Newser
Scilex (NASDAQ:SCLX) Trading 1.1% Higher – Here’s What Happened - Defense World
Even With A 27% Surge, Cautious Investors Are Not Rewarding Scilex Holding Company's (NASDAQ:SCLX) Performance Completely - simplywall.st
Scilex (NASDAQ:SCLXW) Trading Up 0.1% – What’s Next? - Defense World
Scilex Holding Company(NasdaqCM: SCLX) added to Russell 3000E Growth Index - MarketScreener
SCLX registers 1.594M shares & 1.403M warrants; directors re-elected | SCLXW SEC FilingForm 424B3 - Stock Titan
Scilex Holding Company Concludes 2025 Annual Stockholders Meeting - TipRanks
Scilex Defers Record Date for Preferred Stock Dividend - TipRanks
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination - The Manila Times
Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal - The Manila Times
Scilex reports publication on Gloperba dosing adjustments - TipRanks
Scilex announces dosing guide for gout medication GLOPERBA - Investing.com
Scilex Postpones Annual Meeting Due to Quorum Issue - TipRanks
Scilex (NASDAQ:SCLX) Stock Price Down 2.8% – What’s Next? - Defense World
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional - The Manila Times
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL - GlobeNewswire Inc.
New Non-Opioid Pain Treatment SP-102 Demonstrates Superior Efficacy in Latest Clinical Analysis - Stock Titan
Scilex Holding 2025 Q1 Earnings Misses Targets as Net Income Worsens by 7% - AInvest
Scilex Bio signs binding term sheet with NeuroBiogen - TipRanks
Scilex Updates Director Compensation Following Stock Split - TipRanks
Scilex adjusts director compensation post-stock split - Investing.com
Scilex (SCLX) Expected to Announce Quarterly Earnings on Monday - Defense World
Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional - GlobeNewswire
New Clinical Data: Scilex's Non-Opioid SP-102 Shows Promising Results for Chronic Back Pain Treatment - Stock Titan
Scilex Regains Compliance With Nasdaq Listing Rule; Shares Rise - marketscreener.com
Scilex Holding Company Regains Compliance with Nasdaq Minimum Closing Bid Price Requirement - Nasdaq
Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule - GlobeNewswire
Scilex Holding Company’s Market Journey: Closing Weak at 0.24, Down -2.01 - DWinneX
Scilex Adjusts Record Date for Preferred Stock Dividend - TipRanks
Scilex Holding Company Announces New Record Date for Preferred Stock Dividend - Nasdaq
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 202 - The Manila Times
Scilex Holding Company Announces Change in Record Date for - GlobeNewswire
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 202 - Yahoo Finance
Scilex Holding Amends Merger Agreement with Denali By Investing.com - Investing.com Canada
Scilex Holding Amends Merger Agreement with Denali - Investing.com Australia
Scilex Holding Company (SCLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.68%
자본화:
|
볼륨(24시간):